Schrödinger (NASDAQ:SDGR) Announces Quarterly Earnings Results, Misses Expectations By $0.20 EPS

Schrödinger (NASDAQ:SDGR - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20), Zacks reports. The business had revenue of $88.32 million during the quarter, compared to analyst estimates of $83.20 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. Schrödinger updated its FY 2025 guidance to EPS.

Schrödinger Price Performance

Shares of NASDAQ:SDGR traded up $0.06 during trading on Friday, reaching $22.31. The stock had a trading volume of 1,071,695 shares, compared to its average volume of 1,027,856. Schrödinger has a 52 week low of $16.67 and a 52 week high of $29.15. The business's 50-day moving average price is $22.34 and its 200 day moving average price is $20.61. The stock has a market capitalization of $1.63 billion, a PE ratio of -9.53 and a beta of 1.61.

Analyst Ratings Changes

Several analysts have recently commented on the company. BMO Capital Markets raised their target price on Schrödinger from $25.00 to $28.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Piper Sandler cut their price objective on Schrödinger from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday. Finally, KeyCorp increased their price objective on Schrödinger from $25.00 to $27.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $32.29.

Remove Ads

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.